『ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research』のカバーアート

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

著者： American College of Cardiology
無料で聴く

このコンテンツについて

 The American College of Cardiology offers select interviews and summaries of cardiology’s most interesting research areas from ACCEL’s renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.American College of Cardiology Foundation. All rights reserved. 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Primary Results From the SOUL Randomized Trial

    Primary Results From the SOUL Randomized Trial
    2025/06/24
    The SOUL trial demonstrated that in patients with type 2 diabetes (T2DM) and established atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both, treatment with oral semaglutide significantly reduced the risk of major adverse cardiovascular events (MACE) compared to placebo—without an increase in serious adverse events. These findings position oral semaglutide as a compelling option with cardiovascular benefits consistent with those seen in injectable GLP-1 receptor agonists. In this episode, Drs. Deepak L. Bhatt and Darren K. McGuire explore how the SOUL trial further strengthens the favorable risk-benefit profile of oral semaglutide for patients with T2DM and coexisting ASCVD and/or CKD, highlighting its potential to reshape cardiovascular risk management in this high-risk population. SUGGESTED MATERIALS McGuire DK, Marx N, Mulvagh SL, et al.; SOUL Study Group. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025 Mar 29. doi: 10.1056/NEJMoa2501006. Epub ahead of print. Subscribe on Apple Podcasts | Subscribe to ACCEL
    続きを読む 一部表示
    12 分
  • Clopidogrel Versus Aspirin For Long-term Maintenance Monotherapy In Patients With High Ischemic Risk After PCI

    Clopidogrel Versus Aspirin For Long-term Maintenance Monotherapy In Patients With High Ischemic Risk After PCI
    2025/06/17
    The SMART-CHOICE 3 trial demonstrated that clopidogrel monotherapy is more effective than aspirin monotherapy in reducing the risk of major adverse cardiac and cerebrovascular events in high-risk patients who completed standard dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI). Despite concerns that more potent antiplatelet agents may increase bleeding risk, the study found that clopidogrel significantly reduced ischemic events—including myocardial infarction and all-cause death—without increasing bleeding risk, making it a highly favorable option for long-term maintenance therapy. In this episode, Drs. Allen J. Taylor and Joo-Yong Hahn discuss the clinical implications of these findings and offer insights into selecting the optimal single antiplatelet regimen after PCI. SUGGESTED MATERIALS Choi H, Park H, Lee JY, et al. Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial. Lancet. 2025;405(10486):1252-63. doi: 10.1016/S0140-6736(25)00449-0. Koo BK, Kang J, Park KW, et al.; HOST-EXAM investigators. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021;397(10293):2487-2496. doi: 10.1016/S0140-6736(21)01063-1. Subscribe on Apple Podcasts | Subscribe to ACCEL
    続きを読む 一部表示
    9 分
  • Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation

    Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation
    2025/06/10
    The DapaTAVI trial, conducted across 39 centers in Spain, is the first study to evaluate the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, specifically dapagliflozin, in patients with heart failure undergoing transcatheter aortic valve implantation (TAVI). The trial found that patients who received dapagliflozin (10 mg daily) within 14 days of hospital discharge after TAVI experienced a 28% relative risk reduction in the composite outcome of all-cause mortality or worsening heart failure at one year, compared to those receiving standard care In this episode, Drs. Allen J. Taylor and Sergio Raposeiras Roubin discuss the safety and clinical benefits of initiating dapagliflozin—or other SGLT-2 inhibitors—in patients undergoing TAVI who are at risk for heart failure, emphasizing its potential to improve outcomes in this high-risk population. SUGGESTED MATERIALS Raposeiras-Roubin S, Amat-Santos IJ, Rossello X, et al.; the DapaTAVI Investigators. Dapagliflozin in patients undergoing transcatheter aortic-valve implantation. N Engl J Med 2025;392:1396-14. Doi: 10.1056/NEJMoa2500366 Subscribe on Apple Podcasts | Subscribe to ACCEL
    続きを読む 一部表示
    9 分

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Researchに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。